Karyopharm Therapeutics | KPTI - Interest Expense On Debt


Karyopharm Therapeutics reported $12.62M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Abbott USD 42M 2M Dec/2025
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
GlaxoSmithKline GBP 188M 21M Dec/2025
Incyte USD 582K 10K Dec/2025
J&J USD 18M 290M Sep/2025
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 412M 85M Dec/2025
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novartis USD 304M 23M Dec/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Takeda JPY 123.63B 40.49B Dec/2025
Tectonic Therapeutic USD 12K 276.99M Dec/2025
TG Therapeutics USD 6.53M 187K Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Xencor USD 7.35M 311K Dec/2025